BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 32063100)

  • 1. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 2. The health economic impact of varying levels of adherence to colorectal screening on providers and payers.
    Hathway JM; Miller-Wilson LA; Yao W; Jensen IS; Weinstein MC; Parks PD
    J Med Econ; 2021; 24(1):69-78. PubMed ID: 33970747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
    Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
    Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
    Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
    Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
    Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
    J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
    Prince M; Lester L; Chiniwala R; Berger B
    World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
    Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
    Berger BM; Parton MA; Levin B
    Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.
    Finney Rutten LJ; Jacobson RM; Wilson PM; Jacobson DJ; Fan C; Kisiel JB; Sweetser S; Tulledge-Scheitel SM; St Sauver JL
    Mayo Clin Proc; 2017 May; 92(5):726-733. PubMed ID: 28473037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of screening and follow-up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC-AIM microsimulation model.
    Fisher DA; Saoud L; Hassmiller Lich K; Fendrick AM; Ozbay AB; Borah BJ; Matney M; Parton M; Limburg PJ
    Cancer Med; 2021 Apr; 10(8):2855-2864. PubMed ID: 33314646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.
    Piscitello A; Saoud L; Fendrick AM; Borah BJ; Hassmiller Lich K; Matney M; Ozbay AB; Parton M; Limburg PJ
    PLoS One; 2020; 15(12):e0244431. PubMed ID: 33373409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People.
    Redwood DG; Asay ED; Blake ID; Sacco PE; Christensen CM; Sacco FD; Tiesinga JJ; Devens ME; Alberts SR; Mahoney DW; Yab TC; Foote PH; Smyrk TC; Provost EM; Ahlquist DA
    Mayo Clin Proc; 2016 Jan; 91(1):61-70. PubMed ID: 26520415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget Impact Analysis of Against Colorectal Cancer In Our Neighborhoods (ACCION): A Successful Community-Based Colorectal Cancer Screening Program for a Medically Underserved Minority Population.
    Kim B; Lairson DR; Chung TH; Kim J; Shokar NK
    Value Health; 2017 Jun; 20(6):809-818. PubMed ID: 28577699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
    Pickhardt PJ; Correale L; Hassan C
    AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests.
    Fendrick AM; Vahdat V; Chen JV; Lieberman D; Limburg PJ; Ozbay AB; Kisiel JB
    Popul Health Manag; 2023 Aug; 26(4):239-245. PubMed ID: 37466476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.
    Redwood DG; Blake ID; Provost EM; Kisiel JB; Sacco FD; Ahlquist DA
    J Prim Care Community Health; 2019; 10():2150132719884295. PubMed ID: 31646933
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of increasing multitarget stool DNA use among colorectal cancer screeners in a self-insured US employer population.
    Hathway JM; Miller-Wilson LA; Sharma A; Jensen IS; Yao W; Raza S; Parks PD; Weinstein MC
    J Mark Access Health Policy; 2021; 9(1):1948670. PubMed ID: 34512929
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.